Advanced Cell Technology, Inc. (OTCBB: ACTC)
Advanced Cell Technology, Inc. is a biotechnology company. Millions of people globally depend on ACTC’s development of cellular therapies for the treatment of diseases and conditions. To bring patient-specific therapies from the laboratory to the patient, ACTC applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine.
Advanced Cell Technology, one of the heaviest traded penny stocks of 2012, will be presenting at the EBD Group Biotech Showcase™ 2012 in San Francisco, California, on Tuesday, January 10 at 2:00pm. The Biotech Showcase™ gives an opportunity for public, as well as private, life science companies to present to an audience of investors and business development executives at the industry’s largest annual healthcare investor conference. Now in its fourth year, the Biotech Showcase 2012 is projected to attract upwards of 1,500 attendees.
Therapeutic Platforms
Documented in the Nature and Cell Stem Cell journals, called the “single-cell blastomere” technique, ACTC developed and holds in its repertoire the first-ever, proven alternative method for successful hESC generation without harm to the embryo on which it holds broad intellectual property (IP) protection. Based on ground breaking stem cell technology, ACTC has three cellular product platforms:
- Commercializing its human embryonic stem cell (hESC)-based Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease for which it recently initiated two Phase 1/2 clinical trials
- Developing its human embryonic stem cell (hESC)-based Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. ACTC is developing this program in partnership with CHA Biotech of Korea
- Advancing its Phase 2-approved Myoblast autologous adult stem cell therapy for the treatment of chronic heart-failure, advanced cardiac disease, myocardial infarction, and ischemia
Based in Marlborough, MA, Advanced Cell Technology’s stock is traded under the symbol ACTC on the Over-The-Counter Bulletin Board (OTCBB) Stock Exchange and has 22 listed full time employees.
Website: http://www.advancedcell.com
Youtube Feature from Bloomberg TV January, 2011: Click Here To View
Company Snapshot:
| Trading Symbol: | OTCBB: ACTC |
| Last Price: | $0.1399 |
| Avg Vol (3 month): | 8,076,960 |
| Avg Vol (10 day): | 11,461,900 |
| Market Cap: | 235.96M |
| EBITDA (ttm)6: | -17.44M |
| Total Cash (mrq): | $13.90M |
| Shares Outstanding: | 1.69 billion shares |
| Float: | 1.55 Billion shares |
| Top Institutional Holder: | 125,000 shares ZWJ Investment Counsel (as of 9/30/2011) |
| Contact Information: | 33 Locke Drive Marlborough, MA 01752 USA |
| Investor/Analyst inquiries: | James Young 212-732-4300 jyoung@ceocast.com |
| Analyst Recommendations: | (current month) |
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 0 |
| Underperform | 0 |
| Sell | 0 |
Recently ACTC entered into settlement agreements with 40 shareholders of certain warrants and debentures. According to the agreements, ACTC, in exchange for a mutual two-way release of any current and/or future claims, will issue approximately 240.5 million new shares to this group of holders. ACTC also filed a preliminary proxy to increase the authorized shares of the company in order to meet the terms of the settlement agreements.
With patents, agreements, and potential joint ventures, ACTC is in the infant stages of positioning their worldwide network. Other unfunded stem cell therapies for chronic heart failure, advanced cardiac disease, and cardiovascular disease are waiting in the wings. The key component for ACTC to “boom” is the macular degeneration trials. If ACTC is successful in these trials as they have suggested, ACTC will fulfill an unmet medical need in a market worth over $30 billion in the U.S.
Add the rest of the world and take these possible new cash flows and apply them to the unfunded studies above and you have the makings of a colossal company.
About AimHighProfits.com
AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential. Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.
We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.
Aim High Profits Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
ShareJAN
